Abstract
Herpes simplex virus type 1 (HSV-1) is a human pathogen whose lifestyle is based on a long-term dual interaction with the infected host, being able to establish both lytic and latent infections. The virus genome is a 153 kbp double-stranded DNA molecule encoding more than 80 genes. The interest of HSV-1 as gene transfer vector stems from its ability to infect many different cell types, both quiescent and proliferating cells, the very high packaging capacity of the virus capsid, the outstanding neurotropic adaptations that this virus has evolved, and the fact that it never integrates into the cellular chromosomes, thus avoiding the risk of insertional mutagenesis. Two types of vectors can be derived from HSV-1, recombinant vectors and amplicon vectors, and different methodologies have been developed to prepare large stocks of each type of vector. This chapter summarizes (1) the two approaches most commonly used to prepare recombinant vectors through homologous recombination, either in eukaryotic cells or in bacteria, and (2) the two methodologies currently used to generate helper-free amplicon vectors, either using a bacterial artificial chromosome (BAC)-based approach or a Cre/loxP site-specific recombination strategy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roizman, B., and Knipe, D.M. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM (eds). Fields Virology. Lippincot, Williams and Wilkins: Philadelphia, PA, 2001, pp. 2399–2460.
Marozin, S., Prank, U., and Sodeik, B. (2004) Herpes simplex virus type 1 infection of polarized epithelial cells requires microtubules and access to receptors present at cell-cell contact sites. J. Gen. Virol. 85, 775–786.
Honess, R.W., and Roizman, B. (1975) Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. Proc. Natl. Acad. Sci. USA. 72, 1276–1280.
Batterson, W., and Roizman, B. (1983) Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J. Virol. 46, 371–377.
Skepper, J.N., Whiteley, A., Browne, H., and Minson, A. (2001) Herpes simplex virus nucleocapsids mature to progeny virions by an envelopment > deenvelopment > reenvelopment pathway. J. Virol. 75, 5697–5702.
Deshmane, S.L., and Fraser, N.W. (1989) During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J. Virol. 63, 943–947.
Farrell, M.J., Dobson, A.T., Feldman, L.T. (1991) Herpes simplex virus latency-associated transcript is a stable intron. Proc. Natl. Acad. Sci. U S A. 88, 790–794.
Umbach, J.L., Kramer, M.F., Jurak, I., Karnowski, H.W., Coen, D.M., and Cullen, B.R. (2008) MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 454, 780–783.
Preston, C.M. (2000) Repression of viral transcription during herpes simplex virus latency. J. Gen. Virol. 8, 1–19.
Todo, T. (2008) Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front. Biosci. 13, 2060–2064.
Burton, E.A., Fink, D.J., and Glorioso, J.C. (2005) Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications. Curr. Opin. Mol. Ther. 7, 326–336.
Oehmig, A., Fraefel, C., and Breakefield, X.O. (2004) Update on herpesvirus amplicon vectors. Mol. Ther. 10, 630–643.
Cuchet, D., Potel, C., Thomas, J. and Epstein, A.L. (2007) HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin. Biol. Ther. 7, 975–995.
Manservigi, R., Argnani, R., Marconi, P. and Epstein, A.L. (2007). Herpesvirus-based vectors for gene transfer, gene therapy, and the development of novel vaccines. In Virus Expression Vectors, pp205–246. Ed. Kathleen L. Hefferon. Transworld Research Network.
Krisky, D.M., Marconi, P.C., Oligino, T.J., Rouse, R.J., Fink, D.J., Cohen, J.B., Watkins, S.C., and Glorioso, J.C. (1998) Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 5, 1517–1530.
Wu, N., Watkins, S.C., Schaffer, P.A., and DeLuca, N.A. (1996) Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70, 6358–6369.
Samaniego, L.A., Neiderhiser, L., and DeLuca N.A. (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72, 3307–3320.
Berto, E., Bozac, A., and Marconi, P. (2005) Development and application of replication-incompetent HSV-1-based vectors. Gene Ther. 12 Suppl 1:S98–S102.
Krisky, D.M., Wolfe, D., Goins, W.F., Marconi, P.C., Ramakrishnan, R., Mata, M., Rouse, R.J., Fink, D.J., and Glorioso, J.C. (1998) Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5,1593–1603.
Advani, S.J., Weischelbaum, R.R., Whitley, R.J., and Roizman, B. (2002) Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin. Microbiol. Infect. 8, 551–563.
Argnani, R., Lufino, M., Manservigi, M., and Manservigi, R. (2005) Replication-competent herpes simplex vectors: design and applications. Gene Ther. 12 Suppl 1:S170–177.
Nawa, A., Luo, C., Zhang, L., Ushjima, Y., Ishida, D., Kamakura, M., Fujimoto, Y., Goshima, F., Kikkawa, F., and Nishiyama, Y. (2008) Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr. Gene Ther. 8, 208–221.
Gage, P.J., Sauer, B., Levine, M., and Glorioso, J.C. (1992) A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J. Virol. 66, 5509–5515.
Rinaldi, A., Marshall, K.R., Preston, C.M. (1999) A non-cytotoxic herpes simplex virus vector which expresses Cre recombinase directs efficient site specific recombination. Virus Res. 65, 11–20.
Stricklett, P.K., Nelson, R.D., and Kohan, D.E. (1998) Site-specific recombination using an epitope tagged bacteriophage P1 Cre recombinase. Gene 215, 415–423.
Krisky, D.M., Marconi, P.C., Oligino, T., Rouse, R.J., Fink, D.J., and Glorioso, J.C. (1997) Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther. 4, 1120–1125.
Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E.A., Tobler, K., Ackermann, M., Breakefield, X.O., and Fraefel, C. (1998) Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Human Gene Ther. 9, 2787–2794.
Tanaka, M., Kagawa, H., Yamanashi, Y., Sata, T., and Kawaguchi, Y. (2003) Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J. Virol. 77, 1382–91.
Fraefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., Wild, P., and Geller, A.I. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70, 7190–7197.
Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X.O., Chiocca, E.A. (2001) Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. 3, 591–601.
Zaupa, C., Revol-Guyot, V. and Epstein, A.L. (2003) Improved packaging system for generation of high levels non-cytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum. Gene Ther. 14, 1049–1063.
Warming, S., Costantino, N., Court, D.L., Jenkins, N.A., and Copeland, N.G. (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36.
Smith, I.L., Hardwicke, M.A., and Sandri-Goldin, R.M. (1992) Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 186, 74–86.
Kashima, T., Vinters, H.V., and Campagnoni, A.T. (1995) Unexpected expression of intermediate filament protein genes in human oligodendroglioma cell lines. J. Neuropathol. Exp. Neurol. 54, 23–31.
McGeoch, D.J., Dalrymple, M.A., Davison, A.J., Dolan, A., Frame, M.C., McNab, D., Perry, L.J., Scott, J.E., and Taylor, P. (1988) The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol. 69, 1531–15374.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC 2011
About this protocol
Cite this protocol
Fraefel, C., Marconi, P., Epstein, A.L. (2011). Herpes Simplex Virus Type 1-Derived Recombinant and Amplicon Vectors. In: Merten, OW., Al-Rubeai, M. (eds) Viral Vectors for Gene Therapy. Methods in Molecular Biology, vol 737. Humana Press. https://doi.org/10.1007/978-1-61779-095-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-095-9_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-094-2
Online ISBN: 978-1-61779-095-9
eBook Packages: Springer Protocols